Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD
Go back to Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 10.77 +0.11 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.66 | 52 Week High | $25.00 | |||
| Open | $10.68 | 52 Week Low | $7.07 | |||
| Day High | $10.86 | P/E | N/A | |||
| Day Low | $10.34 | EPS | $0.00 | |||
| Volume | 792,487 | |||||
